RSS   Newsletter   Contact   Advertise with us
Post Online Media

Ronald Martell to join Cytori board of directors

CytoriCytori Therapeutics, Inc., a regenerative medicine company, announced that Ronald A. Martell has joined the company’s board of directors to serve as an independent director, effective December 27, 2016.
Article continues below

READ MORE KaloBios appoints Ronald Martell as executive chairman

Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals.

Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems' worldwide commercial operations and field sales force to market and commercialize Erbitux with partners Bristol-Myers Squibb and Merck KGaA.

Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology.

At Genentech, he was responsible for building the company's oncology franchise including the launch of Herceptin for metastatic HER-2 positive breast cancer and Rituxan for non-Hodgkin's lymphoma.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy